The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial DOI Creative Commons
Ron T. Gansevoort, David C. Wheeler,

Francisco Martínez Debén

et al.

Nephrology Dialysis Transplantation, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 3, 2024

In chronic kidney disease (CKD) the nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway is impaired. Runcaciguat, an sGC activator, activates heme-free sGC, restoring cGMP production. This phase 2a trial studied efficacy, safety, and tolerability of runcaciguat in CKD patients with or without sodium-glucose co-transporter-2 inhibitor (SGLT2i).

Language: Английский

Diet as a Source of Acrolein: Molecular Basis of Aldehyde Biological Activity in Diabetes and Digestive System Diseases DOI Open Access
Paweł Hikisz, Damian Jacenik

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(7), P. 6579 - 6579

Published: March 31, 2023

Acrolein, a highly reactive α,β-unsaturated aldehyde, is compound involved in the pathogenesis of many diseases, including neurodegenerative cardiovascular and respiratory diabetes mellitus, development cancers various origins. In addition to environmental pollution (e.g., from car exhaust fumes) tobacco smoke, serious source acrolein our daily diet improper thermal processing animal vegetable fats, carbohydrates, amino acids. Dietary intake one main routes human exposure acrolein, which major public health concern. This review focuses on molecular mechanisms activity context its involvement diseases related digestive system, diabetes, alcoholic liver disease, intestinal cancer.

Language: Английский

Citations

11

Role of dietary antioxidants in diabetes: An overview DOI Creative Commons
Mohamed Shafras,

Rasangi Sabaragamuwa,

Mohamed Suwair

et al.

Food Chemistry Advances, Journal Year: 2024, Volume and Issue: 4, P. 100666 - 100666

Published: March 12, 2024

Diabetes mellitus (DM) is a devastating medical condition which has become one of the top ten causes most deaths, with 70 % increase since 2000. DM characterised by elevated plasma glucose levels. The excess levels have been found to causal link development reactive oxygen species leading oxidative stress. Failure body's intracellular antioxidant system compensate for increased stress results in activation stress-sensitive signalling pathways and ultimately cellular damage, leads pathogenesis DM. It evident that naturally occurring dietary antioxidants such as vitamins E, A, C, plant polyphenols, carotenoids, flavonoids, glutathione, alpha-lipoic acid, polyamines all provide significant protection against diabetes. According research, therapy protects beta-cell stress-induced apoptosis, preserves function, reduces diabetic-related complications. As result, use dramatically, not only because their natural therapeutic effects, but also safety concerns associated synthetic antioxidants, well affordability availability. This paper compiled current research on role diabetes significance mitigating effect.

Language: Английский

Citations

4

The role of mitochondrial dysfunction in kidney injury and disease DOI

Xueqian Jia,

Lifu Zhu,

Qixing Zhu

et al.

Autoimmunity Reviews, Journal Year: 2024, Volume and Issue: 23(6), P. 103576 - 103576

Published: June 1, 2024

Language: Английский

Citations

4

Deoxynivalenol-mediated kidney injury via endoplasmic reticulum stress in mice DOI Creative Commons
Qingbo Zhao,

Siyi Zhang,

Weili Feng

et al.

Ecotoxicology and Environmental Safety, Journal Year: 2024, Volume and Issue: 286, P. 117243 - 117243

Published: Oct. 23, 2024

Language: Английский

Citations

4

The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial DOI Creative Commons
Ron T. Gansevoort, David C. Wheeler,

Francisco Martínez Debén

et al.

Nephrology Dialysis Transplantation, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 3, 2024

In chronic kidney disease (CKD) the nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway is impaired. Runcaciguat, an sGC activator, activates heme-free sGC, restoring cGMP production. This phase 2a trial studied efficacy, safety, and tolerability of runcaciguat in CKD patients with or without sodium-glucose co-transporter-2 inhibitor (SGLT2i).

Language: Английский

Citations

4